Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys
China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...
Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda
China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme...
AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....
CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Shanghai Best-Link Bioscience Secures $29 Million in Series A Financing for Nano Drug Innovation
Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai,...
OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial
US-based OncoSec Medical Inc., (OTCMKTS: ONCSQ), majority-owned by China-based Grand Pharmaceutical Group Ltd (HKG: 0512),...
Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board...
Beijing-Tianjin-Hebei Alliance Completes VBP Tender for Coronary Intervention Devices with 78.29% Price Cut
The Beijing-Tianjin-Hebei “3+N” allied region has completed a volume-based procurement (VBP) tender for coronary catheters,...
Jacobio Pharma Receives Approval for Phase I/IIa Study of LIF mAb in Advanced Solid Tumors
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase...
Nanjing Zenshine Pharmaceuticals’ ZX-7101A Meets Primary Endpoint in Phase II Influenza Study
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd announced that a Phase II...
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract...
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned...
SPH CanSinoBio Suspends COVID-19 Vaccine Production for 180 Days Amid Market Shifts
SPH CanSinoBio, a joint venture between Shanghai Pharmaceuticals Group (SHA: 601607, HKG: 2607) and CanSino...
CNBG and Sinopharm Form Partnership to Integrate Medical Industries
China National Biotec Group Company Ltd (CNBG) has announced a strategic partnership with its parent...
Beijing’s Surgerii Secures Series C3 Financing to Advance Endoscopic Surgical Robot Technology
Beijing-based endoscopic surgical robot developer, Beijing Surgerii Robotics Company Limited, has reportedly raised hundreds of...
Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...
BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets
Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that...
China’s Life Expectancy on Track to Surpass 81.3 Years by 2035, Study Reveals
A recent study published in The Lancet has provided updated forecasts for life expectancy in...
Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics
Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly...